Migraine – Current Treatment – Detailed, Expanded Analysis – Migraine Prophylaxis (US)

According to DRG epidemiology, more than 30 million people in the United States experience migraines, and more than 10% of migraineurs have chronic migraine (CM). Migraine prophylaxis is a core treatment approach for high-frequency episodic and CM patients to reduce migraine frequency, severity, and duration. Current drug treatment primarily includes a mix of off-label and approved drugs from a range of drug classes, including antiepileptic drugs, beta blockers, antidepressants, AbbVie / Allergan’s Botox, and multiple anti-CGRP monoclonal antibodies (MAbs), the first migraine-specific preventive brands. Prophylactic treatment is evolving as the number of agents from which to choose increases. With new oral CGRP receptor antagonists (Biohaven’s Nurtec ODT, AbbVie / Allergan’s atogepant) poised to enter the prophylactic segment, understanding patient pathways and the drivers of treatment decision-making are key for new players bringing novel brands to this large, underserved, and mostly generic market.


  • What patient share do oral standards of care and invasive brands garner overall and by line of therapy in migraine patients initiating treatment?
  • What are the drivers and constraints influencing physicians’ treatment decisions for migraine prophylaxis in the United States?
  • What role do Botox and the anti-CGRP MAbs play in the evolving treatment algorithm? Which MAb garners the most use and why?
  • What percentage of migraine patients are treated with monotherapy versus combination therapy? How long are migraineurs treated with prophylaxis?


Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.

Table of contents

  • Migraine - Current Treatment - Detailed, Expanded Analysis - Migraine Prophylaxis (US)
    • Current Treatment Physician Insights Migraine Prophylaxis US April 2021

Login to access report

launch Related Market Assessment Reports